// App-Quantinova.ai

S197 : NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY

Researchers

Presenter

  • Francesco Passamonti

Principal Investigators

  • James Foran

  • Anand Tandra

  • Valerio De Stefano

  • Maria Laura Fox

  • Ahmad Mattour

  • Mary Frances McMullin

  • Andrew C. Perkins

  • Gabriela Rodriguez-Macas

  • Hassan Sibai

  • Qin Qin

  • Jalaja Potluri

  • Jonathan How

Medical Centers

  • Centre for Medical Education, Queenʼs University Belfast,Belfast,Reino Unido

  • Gastroenterology Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Gastroenterology Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain

  • AbbVie Inc ,North Chicago, IL,Stati Uniti

  • AbbVie Inc., North Chicago, Illinois, United States

  • Myeloma Research Group, Australian Centre for Blood Diseases, Monash University and the Alfred Hospital, Melbourne, Australia

  • Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto,Tor

  • Henry Ford Hosp, Detroit, MI

  • AbbVie Inc ,North Chicago, IL,États-unis

  • AbbVie Inc ,North Chicago, IL,Estados Unidos

  • AbbVie, Inc., North Chicago, IL

  • Gastroenterology, Mc Gill University Health Center, Montreal, Quebec, Canada

  • Henry Ford Hospital,Detroit, MI,États-unis

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Division of Hematology, McGill Universit

  • Department of Medicine and Surgery,

  • Gastroenterology, Mc Gill University Health Center, Montreal, Quebec, Canada

  • Department of Hematology, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus ,Barcelona,Espagne

  • Henry Ford Hospital, Detroit, Michigan, United States

  • AbbVie Inc ,North Chicago, IL,États-unis

  • AbbVie Inc ,North Chicago, IL,Estados Unidos

  • Gastroenterology Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain

  • Henry Ford Hospital,Detroit, MI,Verenigde Staten

  • Henry Ford Hospital,Detroit, MI,Verenigde Staten

  • Department of Hematology, Vall d’Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

  • Indiana Blood and

  • Gastroenterology, Mc Gill University Health Center, Montreal, Quebec, Canada

  • Section of Hematology, Department of Radiological and Hematological S

  • Centre for Medical Education, Queenʼs University Belfast,Belfast,Reino Unido

  • Henry Ford Hospital,Detroit, MI,États-unis

  • Centre for Medical Education, Queenʼs University Belfast,Belfast,Reino Unido

  • Mayo Clinic, Jacksonville, Jacksonville, Florida, United States

  • Mayo Clinic,Jacksonville, FL,Stati Uniti

  • Section of Hematology, Department of Radiological and Hematological Sciences ,Catholic University of the Sacred Heart,Rome,Italien

  • Gastroenterology Unit, Hospital General Universitario Gregorio Maranon, Madrid, Spain

  • Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • Section of Hematology, Department of Radiological and Hematological Sciences ,Catholic University of the Sacred Heart,Rome,Italien

  • Department of Medicine and Surgery, University of Insubria, Varese, Italy

  • Mayo Clinic-Florida,Jacksonville,Verenigde Staten

  • Department of Medicine and Surgery, University of Insubria, Varese, Italy

  • Indiana Blood and Marrow Transplant,Indianapolis,Estados Unidos

  • Section of Hematology, Department of Radiological and Hematological Sciences ,Catholic University of the Sacred Heart,Rome,Italien

  • Australian Center for Blood Diseases, Monash University, The Alfred Hospital, Melbourne, VIC, Australia

  • Mayo Clinic-Florida,Jacksonville,États-unis

  • Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

  • AbbVie Inc., North Chicago, Illinois, United States

  • Department of Medicine and Surgery, University of Insubria, Varese, Italy

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Centre for Medical Education, Queenʼs University Belfast,Belfast,Reino Unido

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Department of Hematology, Hospital General Univ

  • Indiana Blood and Marrow Transplant,Indianapolis,Estados Unidos

  • Medicine,Mayo Clinic,Jacksonville,Estados Unidos

  • Henry Ford Hospital,Detroit, MI,Estados Unidos

  • Department of Medicine and Surgery, University of Insubria, Varese, Italy

  • AbbVie, Inc., North Chicago, IL

  • Mayo Clinic-Florida,Jacksonville,Verenigde Staten

  • Department of hematology,Hospital Clíni

  • Myeloma Research Group, Australian Centre for Blood Diseases, Monash University and the Alfred Hospital, Melbourne, Australia

  • Centre for Medical Education,Queen's University,Belfast,United Kingdom

  • Mayo Clinic, Jacksonville, FL

  • AbbVie Inc ,North Chicago, IL,Stati Uniti

  • Indiana Blood and Marrow Transplant,Indianapolis,Estados Unidos

Locations

  • Italy

  • United States

  • Palestine

  • United Kingdom

  • Australia

  • Spain

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Myelofibrosis

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • Ruxolitinib phosphate

  • Navitoclax

Outcome

  • N/A

Study Design

  • Open Label

  • Multinational

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03222609

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved